Rebecca G Bagley

Summary

Affiliation: Genzyme Corporation
Country: USA

Publications

  1. ncbi Endothelial precursor cells as a model of tumor endothelium: characterization and comparison with mature endothelial cells
    Rebecca G Bagley
    Genzyme Corp, Framingham, Massachusetts 01701-9322, USA
    Cancer Res 63:5866-73. 2003
  2. ncbi Tumor endothelial marker 7 (TEM-7): a novel target for antiangiogenic therapy
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Ave, Framingham, MA 01701, USA
    Microvasc Res 82:253-62. 2011
  3. ncbi Human choriocarcinomas: placental growth factor-dependent preclinical tumor models
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Ave, Framingham, MA 01701 9322, USA
    Int J Oncol 40:479-86. 2012
  4. ncbi Endosialin: from vascular target to biomarker for human sarcomas
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01710 9322, USA
    Biomark Med 3:589-604. 2009
  5. ncbi Placental growth factor upregulation is a host response to antiangiogenic therapy
    Rebecca G Bagley
    Genzyme Corporation, Framingham, Massachusetts 01701, USA
    Clin Cancer Res 17:976-88. 2011
  6. ncbi sFLT01: a novel fusion protein with antiangiogenic activity
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Ave, Framingham, MA 01701, USA
    Mol Cancer Ther 10:404-15. 2011
  7. ncbi Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs
    Rebecca G Bagley
    Genzyme Corporation, Framingham, MA 01701, USA
    Int J Oncol 34:1329-40. 2009
  8. ncbi Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Ave, Framingham, MA 01701 9322, USA
    Cancer Chemother Pharmacol 68:1537-46. 2011
  9. ncbi Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers
    Rebecca G Bagley
    Genzyme Corporation, Framingham, MA 01701 9322, USA
    Int J Oncol 34:619-27. 2009
  10. ncbi Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Avenue Framingham, MA 01701 9322, USA
    Microvasc Res 76:180-8. 2008

Collaborators

Detail Information

Publications19

  1. ncbi Endothelial precursor cells as a model of tumor endothelium: characterization and comparison with mature endothelial cells
    Rebecca G Bagley
    Genzyme Corp, Framingham, Massachusetts 01701-9322, USA
    Cancer Res 63:5866-73. 2003
    ..EPC may be a better model of human tumor endothelial cells than HUVEC and HMVEC and, thus, may provide an improved cell-based model for second generation antineoplastic antiangiogenic drug discovery...
  2. ncbi Tumor endothelial marker 7 (TEM-7): a novel target for antiangiogenic therapy
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Ave, Framingham, MA 01701, USA
    Microvasc Res 82:253-62. 2011
    ..These data demonstrate that TEM-7 is a vascular protein associated with angiogenic states. TEM-7 is a novel and attractive target for antiangiogenic therapy...
  3. ncbi Human choriocarcinomas: placental growth factor-dependent preclinical tumor models
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Ave, Framingham, MA 01701 9322, USA
    Int J Oncol 40:479-86. 2012
    ....
  4. ncbi Endosialin: from vascular target to biomarker for human sarcomas
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01710 9322, USA
    Biomark Med 3:589-604. 2009
    ..Thus, endosialin holds potential value both as a therapeutic target and as a biomarker for certain human cancers...
  5. ncbi Placental growth factor upregulation is a host response to antiangiogenic therapy
    Rebecca G Bagley
    Genzyme Corporation, Framingham, Massachusetts 01701, USA
    Clin Cancer Res 17:976-88. 2011
    ..It was tested in syngeneic and xenograft tumor models to evaluate the effects of simultaneously neutralizing PlGF and VEGF-A and to investigate changes observed in the clinic in preclinical models...
  6. ncbi sFLT01: a novel fusion protein with antiangiogenic activity
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Ave, Framingham, MA 01701, USA
    Mol Cancer Ther 10:404-15. 2011
    ..It is a dual targeting agent that neutralizes both VEGF and PlGF and, therefore, has potential as a next generation antiangiogenic therapeutic for oncology...
  7. ncbi Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs
    Rebecca G Bagley
    Genzyme Corporation, Framingham, MA 01701, USA
    Int J Oncol 34:1329-40. 2009
    ..Bringing together bone marrow toxicity data, tumor cell line cytotoxicity data, and human tumor xenograft efficacy provides valuable information for the translation of preclinical findings to the clinic...
  8. ncbi Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Ave, Framingham, MA 01701 9322, USA
    Cancer Chemother Pharmacol 68:1537-46. 2011
    ..To investigate the activity and myeloprotective properties of erufosine, a novel alkylphosphocholine (APC), on human malignant cells and normal bone marrow cells...
  9. ncbi Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers
    Rebecca G Bagley
    Genzyme Corporation, Framingham, MA 01701 9322, USA
    Int J Oncol 34:619-27. 2009
    ..Endosialin expression by both CAF and MSC further implies the potential contribution of MSC to tumor stroma via differentiation into tumor stromal fibroblasts...
  10. ncbi Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Avenue Framingham, MA 01701 9322, USA
    Microvasc Res 76:180-8. 2008
    ..Anti-endosialin antibodies may have value in identifying vasculature in malignant tissues. With the appropriate agent, targeting endosialin may interfere with blood vessel growth during tumor development...
  11. ncbi Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701 9322, USA
    Mol Cancer Ther 7:2536-46. 2008
    ..The data presented here on endothelial genes that are up-regulated in tumor vasculature and in EPC support the hypothesis that the angiogenesis process in cancer can involve EPC...
  12. ncbi Pericytes from human non-small cell lung carcinomas: an attractive target for anti-angiogenic therapy
    Rebecca G Bagley
    Genzyme Corporation, Framingham, MA 01701 9322, USA
    Microvasc Res 71:163-74. 2006
    ..Pericytes displayed invasive action against NSCLC clusters in the absence of other cell types. Perivascular cells contribute to the progression of disease and are an attractive target for anti-angiogenic therapy...
  13. ncbi Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy
    Rebecca G Bagley
    Genzyme Corp, Framingham, Massachusetts 01701 9322, USA
    Cancer Res 65:9741-50. 2005
    ..These results support the notion that pericytes and EPC contribute to malignancy and that these cell types can be useful as cell-based models for tumor vascular development and selection of agents that may provide therapeutic benefit...
  14. ncbi Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment
    Leslie S Kurtzberg
    Genzyme Corporation, Framingham, Massachussetts 01701, USA
    Clin Cancer Res 17:2777-87. 2011
    ....
  15. ncbi Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors
    Leslie S Kurtzberg
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA
    Mol Cancer Ther 7:3212-22. 2008
    ..This may be due to greater sensitivity of human bone marrow than mouse to the cytotoxicity of these agents. It may be possible to achieve similar levels of ARC-111 in patients as in mice allowing improved antitumor activity...
  16. ncbi Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents
    Leslie S Kurtzberg
    Genzyme Corporation, Framingham, MA 01701, USA
    Cancer Chemother Pharmacol 64:1029-38. 2009
    ..The bone marrow toxicity and human tumor xenograft activity of three tubulin-binding compounds, vincristine, paclitaxel, and tasidotin were compared...
  17. ncbi Expression of TMPRSS4 in non-small cell lung cancer and its modulation by hypoxia
    Tri Hung Nguyen
    Genzyme Corporation, Framingham, MA 01701, USA
    Int J Oncol 41:829-38. 2012
    ..Overall, these results indicate that the cancer-associated TMPRSS4 protein is overexpressed in NSCLC and may represent a potential therapeutic target...
  18. ncbi Characteristics of human Ewing/PNET sarcoma models
    Beverly A Teicher
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA
    Ann Saudi Med 31:174-82. 2011
    ..Ewing PNET sarcomas are a rare disease where models are available...
  19. ncbi Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling
    Cecile Rouleau
    Genzyme Corporation, Framingham, MA, USA
    Int J Oncol 39:73-89. 2011
    ..These results demonstrate for the first time that endosialin is a suitable therapeutic target for poor prognosis and advanced disease...